Iressa in NSCLC is another case in point. Getting a new cancer drug approved based on data from a single arm trial is definitely getting harder especially with no survival data. The drug needs to show a very very high response rate or to aim at an unmet medical need.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.